Jump to main content
Jump to site search

Issue 13, 2017
Previous Article Next Article

A high throughput immunoassay for the therapeutic drug monitoring of tegafur

Author affiliations

Abstract

Cancer is a group of diseases in which abnormal cells grow and divide without control, with the potential to invade other parts of the body. Chemotherapy is a type of treatment that uses chemical agents to treat cancer. These drugs are toxic and produce undesirable adverse drug reactions due to their narrow therapeutic window and highly variable pharmacokinetics, thus, they need to be monitored to establish personalized treatment to achieve maximal efficiency and reduce drug toxicity. Nowadays, therapeutic drug monitoring (TDM) is not routinely used for chemotherapy agents, however, TDM has the potential to improve the clinical benefit of chemotherapy drugs. Tegafur, a prodrug of 5-fluorouracil (5FU), is one of the main anti-cancer drugs used worldwide. Herein, a reproducible and sensitive indirect competitive ELISA has been developed and validated in plasma samples. The assay reports an IC50 of 35.6 nM, reaching a limit of detection of 2.7 nM. It is highly reproducible and does not show cross-reactivity with any related compound. In summary, this assay provides a sensitive, accurate and high throughput analytical method for tegafur quantification in plasma, which fits TDM requirements.

Graphical abstract: A high throughput immunoassay for the therapeutic drug monitoring of tegafur

Back to tab navigation

Supplementary files

Publication details

The article was received on 09 Mar 2017, accepted on 03 May 2017 and first published on 10 May 2017


Article type: Paper
DOI: 10.1039/C7AN00418D
Citation: Analyst, 2017,142, 2404-2410
  •   Request permissions

    A high throughput immunoassay for the therapeutic drug monitoring of tegafur

    M. Broto, R. McCabe, R. Galve and M.-Pilar Marco, Analyst, 2017, 142, 2404
    DOI: 10.1039/C7AN00418D

Search articles by author

Spotlight

Advertisements